Intrexon Announces Second Quarter and First Half 2016 Financial Results Quarterly revenues of $52.5 million and GAAP net loss of $49.1 million including non-cash charges of $44.0 million Adjusted EBITDA of $110.7 million

Intrexon Announces Second Quarter and First Half 2016 Financial Results

Quarterly revenues of $52.5 million and GAAP net loss of $49.1 million

including non-cash charges of $44.0 million

Adjusted EBITDA of $110.7 million

GERMANTOWN, MD, August 9, 2016 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to

improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.

Highlights and Recent Developments:

Quarter Financial Highlights:

First Half Financial Highlights:

We began the year with great anticipation that 2016 will be a period in which we should demonstrate significant progress on several dimensions,

commented Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, and so far are tracking very well against our objectives. While continuing our trajectory of growing financial performance and capital efficiency, we have advanced

many of our programs, achieving key scientific, developmental and regulatory milestones. In addition, our production and marketing plans around three mature yet game-changing assets the Friendly Aedes mosquito, the Arctic apple and the AquAdvantage salmon are being managed aggressively, and we look forward to the world enjoying the benefits of each

of these unique, sustainable and environmentally responsible solutions to major problems.

Mr. Kirk concluded, Considering the poignant

moment in history that we occupy, one in which there is increasing recognition of the need for the engineering of biology to be responsibly practiced in order to solve an enormous number of world problems in areas such as healthcare, food, energy

and the environment, our greatest need in order for Intrexon to play a leading role on this industrial and social vector, is the recruitment and development of great talent at every level of our organization on our board, within our executive

management team and in our labs that today span North America and Europe. In this regard, I am honored every day to work in partnership with our President, Geno Germano, the rest of our executive team and with so many brilliant and dedicated

scientists and professionals throughout our organization. I believe that the world should expect great things from such a team, and I believe that they will deliver on these expectations.

Second Quarter 2016 Financial Results Compared to Prior Year Period

Total revenues were $52.5 million for the quarter ended June 30, 2016 compared to $44.9 million for the quarter ended June 30, 2015, an increase of

$7.6 million, or 17%. Collaboration and licensing revenues increased $10.3 million over the quarter ended June 30, 2015 due to (i) the recognition of deferred revenue for upfront payments received from the Company s license and

collaboration agreement with the biopharmaceutical business of Merck KGaA, which became effective in May 2015, and from other collaborations signed by Intrexon between July 1, 2015 and June 30, 2016; and (ii) increased research and

development services for these collaborations and for the progression of programs or the addition of new programs with previously existing collaborators. Product revenues were $10.9 million for the quarter ended June 30, 2016 compared to $14.3

million for the quarter ended June 30, 2015, a decrease of $3.4 million, or 24%. The decrease in product revenues and gross margin thereon primarily relates to a decrease in the quantities of pregnant cows, livestock previously used in

production and live calves sold due to lower customer demand for these products. The decreases were partially offset by an increase in the quantity of weaned calves sold due to higher customer demand. Service revenues were $13.9 million for the

quarter ended June 30, 2016 compared to $13.3 million for the quarter ended June 30, 2015, an increase of $0.6 million, or 5%. The increase relates to an increase in the number of in vitro fertilization cycles performed due to

higher customer demand.

Total operating expenses were $75.7 million for the quarter ended June 30, 2016 compared to $62.3 million for the quarter

ended June 30, 2015, an increase of $13.4 million, or 22%. Research and development expenses increased $8.0 million, or 39%, due primarily to increases in (i) salaries, benefits and other personnel costs for research and development

employees, (ii) lab supplies and consulting expenses, and (iii) depreciation and amortization. Salaries, benefits and other personnel costs increased $2.3 million due to (i) an increase in research and development headcount to support

new and expanded collaborations and (ii) costs for research and development employees assumed in the Company s acquisition of Oxitec Limited, or Oxitec, in September 2015. Lab supplies and consulting expenses increased $3.4 million as a

result of (i) the progression into the preclinical phase with certain of Intrexon s collaborators; (ii) the increased level of research and development services provided to the Company s collaborators; and (iii) costs

incurred as a result of the Company s September 2015 acquisition of Oxitec. Depreciation and amortization increased $1.9 million primarily as a result of (i) the inclusion of a full quarter of depreciation and amortization on property and

equipment and intangible assets

acquired in the Company s 2015 acquisitions, and (ii) amortization related to AquaBounty s intangible assets upon regulatory approval in November 2015. Selling, general and

administrative (SG&A) expenses increased $6.6 million, or 28%, over the second quarter of 2015. Legal and professional expenses increased $5.8 million due to (i) consulting expenses payable in shares of Intrexon s common stock pursuant

to the Company s services agreement with Third Security, LLC, or Third Security, which the Company entered into in November 2015; (ii) expenses incurred to support domestic and international government affairs for regulatory and other

approvals necessary to commercialize the Company s products and services; (iii) increased legal fees incurred to defend ongoing litigation; and (iv) incremental costs incurred to support the ongoing operations of the Company s

2015 acquisitions and other business development activities. These increases were partially offset by a decrease of $2.2 million for salaries, benefits and other personnel costs. Salaries, benefits and other personnel costs for SG&A employees

decreased primarily due to a decrease in stock compensation and other compensation expenses resulting primarily from the departure of certain officers of the Company. These decreases were partially offset by increased headcount, including a new

executive officer to support the Company s expanding operations as well as the acquisition of Oxitec in September 2015.

First Half 2016 Financial

Results Compared to Prior Year Period

Total revenues were $95.9 million for the six months ended June 30, 2016 compared to $78.7 million for the

six months ended June 30, 2015, an increase of $17.2 million, or 22%. Collaboration and licensing revenues increased $19.6 million over the six months ended June 30, 2015 due to (i) the recognition of deferred revenue for upfront

payments received from the Company s license and collaboration agreement with the biopharmaceutical business of Merck KGaA, which became effective in May 2015, and from other collaborations signed by Intrexon between July 1, 2015 and

June 30, 2016; and (ii) increased research and development services for these collaborations and for the progression of programs or the addition of new programs with previously existing collaborators. Product revenues were $19.4 million

for the six months ended June 30, 2016 compared to $23.2 million for the six months ended June 30, 2015, a decrease of $3.8 million, or 16%. The decrease in product revenues and gross margin thereon primarily relates to a decrease in the

quantities of pregnant cows, livestock previously used in production and live calves sold due to lower customer demand for these products. The decreases were partially offset by an increase in the quantity of weaned calves sold due to higher

customer demand. Service revenues were $24.6 million for the six months ended June 30, 2016 compared to $23.2 million for the six months ended June 30, 2015, an increase of $1.4 million, or 6%. The increase relates to an increase in the

number of in vitro fertilization cycles performed due to higher customer demand.

Total operating expenses were $159.7 million for the six months

ended June 30, 2016 compared to $183.3 million for the six months ended June 30, 2015, a decrease of $23.6 million, or 13%. Research and development expenses declined $45.5 million, or 46%, due primarily to the inclusion in 2015 of a $59.6

million payment In common stock for an exclusive license to certain technologies owned by the University of Texas MD Anderson Cancer Center. This decrease was partially offset by increases in (i) salaries, benefits and other personnel costs for

research and development employees, (ii) lab supplies and consulting expenses, and (iii) depreciation and amortization. Salaries, benefits and other personnel costs increased $4.6 million due to (i) an increase in research and

development headcount to support new and expanded collaborations and (ii) costs for research and development employees assumed in the Company s acquisition of Oxitec in September 2015. Lab supplies and consulting expenses increased $6.2

million as a result of (i) the progression into the preclinical phase with certain of Intrexon s collaborators; (ii) the increased level of research and development services provided to the Company s collaborators; and

(iii) costs incurred as a result of the Company s September 2015 acquisition of Oxitec. Depreciation and amortization increased $3.8 million primarily as a result of (i) the inclusion of a full period of depreciation and amortization

on property and equipment and intangible assets acquired in the Company s 2015 acquisitions and (ii) amortization related to AquaBounty s intangible assets upon regulatory approval in November 2015. SG&A expenses increased $21.8

million, or 43%, over the six months of 2015. Salaries, benefits and other personnel costs for SG&A employees increased $3.8 million due to (i) increased headcount, including a new executive officer, to support the Company s expanding

operations; (ii) a full period of stock compensation expense for a company-wide option grant to employees in March 2015; and (iii) salaries,

benefits and other personnel costs for employees assumed in the Company s acquisition of Oxitec in September 2015. These increases were partially offset by (i) a decrease in stock

compensation and other compensation expenses resulting primarily from the departure of certain officers of the Company. Legal and professional expenses increased $9.5 million primarily due to (i) consulting expenses payable in shares of

Intrexon s common stock pursuant to the Company s services agreement with Third Security which the Company entered into in November 2015; (ii) expenses incurred to support domestic and international government affairs for regulatory

and other approvals necessary to commercialize the Company s products and services; (iii) increased legal fees incurred to defend ongoing litigation; and (iv) incremental costs incurred to support the ongoing operations of the

Company s 2015 acquisitions and other business development activities. In 2016, the Company also recorded $4.2 million in litigation settlement expenses arising from the entrance of a court order in Trans Ova Genetics, L.C. s trial with

Total other income (expense), net, was $(43.8 million) for the six months ended June 30, 2016 compared to $94.7 million for the six months

ended June 30, 2015, a decrease of $138.5 million, or 146%. This decrease was attributable to the $81.4 million realized gain recognized upon the special stock dividend of all of Intrexon s shares of ZIOPHARM to the Company s

shareholders in June 2015 and the decrease in fair value of the Company s equity securities portfolio.

Conference Call and Webcast

The Company will host a conference call today Tuesday, August 9th, at 5:30 PM EDT to discuss the

second quarter and first half 2016 financial results and provide a general business update. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1-412-317-6061 (International) and providing the

number 7396635 to join the Intrexon Corporation Call. Participants may also access the live webcast through Intrexon s website in the Investors section at http://investors.dna.com/events.

About Intrexon Corporation

Intrexon Corporation (NYSE:

XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet. Intrexon s integrated technology suite provides its partners across diverse

Non-GAAP Financial Measures

This press release presents

Adjusted EBITDA and Adjusted EBITDA per share, which are non-GAAP financial measures within the meaning of applicable rules and regulations of the Securities and Exchange Commission (SEC). For a reconciliation of these measures to the most directly

comparable financial measure calculated in accordance with generally accepted accounting principles and for a discussion of the reasons why the company believes that these non-GAAP financial measures provide information that is useful to investors

see the tables below under Reconciliation of GAAP to Non-GAAP Measures. Such information is provided as additional information, not as an alternative to Intrexon s consolidated financial statements presented in accordance with GAAP,

and is intended to enhance an overall understanding of the Intrexon s current financial performance.

Intrexon, ActoBiotics, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may

be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the

Safe Harbor Provisions of the Private Securities Litigation

Reform Act of 1995. These forward-looking statements are based upon Intrexon s current expectations and projections about future events and generally relate to Intrexon s plans,

objectives and expectations for the development of Intrexon s business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements

involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. These risks and uncertainties include, but are not limited to,

(i) Intrexon s current and future ECCs and joint ventures; (ii) Intrexon s ability to successfully enter new markets or develop additional products, whether with its collaborators or independently; (iii) actual or

anticipated variations in Intrexon s operating results; (iv) actual or anticipated fluctuations in Intrexon s competitors or its collaborators operating results or changes in their respective growth rates;

(v) Intrexon s cash position; (vi) market conditions in Intrexon s industry; (vii) the volatility of Intrexon s stock price; (viii) Intrexon s ability, and the ability of its collaborators, to protect

Intrexon s intellectual property and other proprietary rights and technologies; (ix) Intrexon s ability, and the ability of its collaborators, to adapt to changes in laws or regulations and policies; (x) the outcomes of pending

or future litigation; (xi) the rate and degree of market acceptance of any products developed by a collaborator under an ECC or through a joint venture; (xii) Intrexon s ability to retain and recruit key personnel;

(xiii) Intrexon s expectations related to the use of proceeds from its public offerings and other financing efforts; (xiv) Intrexon s estimates regarding expenses, future revenue, capital requirements and needs for additional

financing; and (xv) Intrexon s expectations relating to its subsidiaries and other affiliates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Intrexon s actual results to

differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Intrexon s Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in

Intrexon s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intrexon undertakes no duty to update this information unless required by law.

For more information regarding Intrexon